摘要
目的:探讨miR-195在乳腺浸润性导管癌患者术前、术后2周血浆中的表达及其与乳腺癌临床病理特征的相关性。方法:以miR-16为内参,采用茎环RT-qPCR方法检测48例术前、术后2周乳腺浸润性导管癌患者及35例健康对照者血浆中miR-195的表达,并分析其表达与乳腺浸润性导管癌临床病理指标的关系。结果:乳腺浸润性导管癌患者血浆中miR-195的表达较健康对照者明显升高(P<0.05),术后2周表达明显降低至健康对照者水平。ROC曲线显示,血浆miR-195评价乳腺浸润性导管癌的敏感性和特异性可达94.4%和68.8%。与临床特征相关性分析统计未见血浆miR-195表达与乳腺浸润性导管癌肿块大小、雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体-2(Her-2)状态及淋巴结转移状态等临床病理特征有明显相关(P>0.05)。结论:血浆中miR-195的异常表达可作为乳腺癌诊断的新的肿瘤标志物。
Objective： To explore the expression of miR-195 in plasma of patients with breast cancer in pre-operative and postoperative and two weeks and it correlation with clinicopathologic features of breast cancer. Methods： By normalized to miR-16, the expressions of miR-195 in 48 invasive ductal carcinoma of the breast cancer at preoperative and postoperative 2 weeks and 35 healthy controls were examined by stem-loop real-time RT-qPCR method. The relationship between miR-195 expression and clinicopathological characteristics were further analyzed. Results： Expression of miR-195 in plasma of patients with breast cancer was obviously higher than that in the healthy controls （P〈0.05）. At 2 weeks postopratively, a significant decrease of plasma miR-195 was observed, reaching levels of the healthy control subjects. ROC curve showed plasma levels of miR-195 could detect individuals with breast cancer with 94.4% sensitivity and 68.8% specificity. Correlative analysis of clinical features showed that there was no significant association between plasma miR-195 expression and the size of tumor, the state of ER, PR, lymph node metastasis and Her-2 receptor of breast cancer. Conclusion： Aberrant expression of miR-195 in plasma of breast cancer patients has potential use as novel noninvasive biomarkers for breast cancer.
出处
《温州医学院学报》
CAS
2014年第2期105-108,112,共5页
Journal of Wenzhou Medical College
基金
温州市科技计划项目(Y20110119)
